INMB INmune Bio Corporation: Long-Term Debt to Capital Coefficient

INmune Bio, Inc. (INMB) strategy of leveraging cutting-edge immunologists to combat cancer has determined the dynamics of its long-term debt-to-equity ratio, where the metric stands at 0.03. While biopathway patents create a defensive moat against competitors, the high concentration of early-stage development in oncology and Alzheimer's therapy increases financial risks due to the absence of current sales.

This metric determines the company's dependence on long-term borrowings relative to its equity. By analyzing the share of long-term loans within the capital structure, investors assess the debt load risk associated with changes in interest rates. The metric reveals the balance between aggressive financing and financial stability. For INmune Bio, Inc. (INMB), this is critical, as the automation of synthesis does not eliminate the costly, multi-year clinical trials. High leverage here could serve as a tool to accelerate drug development.